Clostridioides difficile (C. difficile) infection (CDI) is a significant healthcare-associated infection, known for its high morbidity and mortality rates, especially in vulnerable populations. CDI ...

Clostridioides difficile (C. difficile) infection (CDI) is a significant healthcare-associated infection, known for its high morbidity and mortality ...

It may take up to two weeks for a bout of C. diff to respond to treatment and for diarrhea to clear up. In the interim, while waiting for treatment to be effective, many people with C. diff eat a ...

A synthetic microbiome therapy, tested in mice, protects against severe symptoms of a gut infection that is notoriously ...

Study authors say the results in immunocompromised patients are consistent with those from previous clinical studies of the ...

A real-world study of patients with Clostridioides difficile infection (CDI) in Australia over 10 years shows that fecal ...

Fzata, Inc. announces the execution of a clinical trial agreement with the National Institutes of Health (NIH) to sponsor a ...

Ferring Inc. announced Health Canada has issued a Notice of Compliance, approving REBYOTA® (fecal microbiota, live), a novel first-in-class microbiome-restoration therapy indicated for the prevention ...

Scientists develop a synthetic microbiome therapy to fight C. difficile infections offering a safer, targeted alternative ...

A: “Hand hygiene” refers to a general term that applies to handwashing, antiseptic handwash, and alcohol-based hand rub (ABHR), according to the Centers for Disease Control and Prevention website and ...

difficile treatment. Oral FZ002 is a live yeast genetically modified to express a tetraspecific anti-toxin for C. difficile in the gastrointestinal (GI) tract. FZ002 is a first-in-class multi ...

demonstrating their deep commitment to the BioPYM FZ002 program and the clinical need for a safer and more effective C. difficile treatment." Dr. Wilbur Chen MD, an adult infectious disease expert ...